Main content

Freshfields advises on Shanghai Pharma’s US$402m H-share placement in Hong Kong

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Shanghai Pharmaceuticals Holding Co. Ltd. (‘Shanghai Pharma’) on its placement of approximately 153m new H-shares on the Hong Kong Stock Exchange. The transaction closed today (26 January 2018) and raised US$402m.

The placing shares represent around 5.7 per cent of the total existing issued share capital. Shanghai Pharma plans to use the proceeds of the placement to fund the development of its pharmaceutical manufacturing and distribution businesses and replenish its working capital.

The Freshfields team advising on the deal was led by Global Transactions partner Richard Wang.

ENDS

Notes for editors

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer LLP is a global law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on ground-breaking and business-critical mandates. Our 2,800 plus lawyers deliver results worldwide through our own offices and alongside leading local firms.  Our commitment, local and multi-national expertise and business know-how means our clients rely on us when it matters most.

 

The Freshfields team was led by: